Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$231 Mln
P/E Ratio
--
P/B Ratio
1.06
Industry P/E
--
Debt to Equity
0.02
ROE
-0.34 %
ROCE
-33.19 %
Div. Yield
0 %
Book Value
5.7
EPS
-1.68
CFO
$-334.55 Mln
EBITDA
$-189.27 Mln
Net Profit
$-360.34 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Astria Therapeutics (ATXS)
| -54.92 | -37.52 | -48.00 | -63.69 | -14.33 | -33.82 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Astria Therapeutics (ATXS)
| 16.26 | -48.42 | 176.25 | -58.02 | -63.79 | 35.24 | -70.47 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.30 | 10,226.85 | 20.76 | 23.13 | |
| 296.72 | 9,219.66 | 24.15 | 58.42 | |
| 24.69 | 10,361.50 | -- | -28.77 | |
| 101.65 | 9,388.25 | 28.84 | 14.16 |
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal... antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. Address: 22 Boston Wharf Road, Boston, MA, United States, 02210 Read more
Co-Founder, CEO, President & Director
Ms. Jill C. Milne Ph.D.
Co-Founder, CEO, President & Director
Ms. Jill C. Milne Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Astria Therapeutics Inc (ATXS) stood at $ 342 Mln as on 31-Dec-24
The share price of Astria Therapeutics Inc (ATXS) is $4.03 (NASDAQ) as of 17-Apr-2025 15:40 EDT. Astria Therapeutics Inc (ATXS) has given a return of -14.33% in the last 3 years.
Astria Therapeutics Inc (ATXS) has a market capitalisation of $ 231 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Astria Therapeutics Inc (ATXS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Astria Therapeutics Inc (ATXS) and enter the required number of quantities and click on buy to purchase the shares of Astria Therapeutics Inc (ATXS).
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. Address: 22 Boston Wharf Road, Boston, MA, United States, 02210
The CEO & director of Ms. Jill C. Milne Ph.D.. is Astria Therapeutics Inc (ATXS), and CFO & Sr. VP is Ms. Jill C. Milne Ph.D..
There is no promoter pledging in Astria Therapeutics Inc (ATXS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Astria Therapeutics Inc. (ATXS) | Ratios |
|---|---|
|
Return on equity(%)
|
-33.52
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Astria Therapeutics Inc (ATXS) was $0 Mln.
$0.05
(
